Published in Intensive Care Med on May 02, 2017
Is it time to implement door-to-needle time for "infection attacks"? Intensive Care Med (2017) 0.75
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med (2006) 23.62
Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev (2012) 10.32
Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med (2010) 6.35
Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA (2008) 6.29
The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Crit Care Med (2015) 6.00
Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA (2001) 5.96
Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med (2014) 5.70
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis (2012) 4.07
A multifaceted intervention for quality improvement in a network of intensive care units: a cluster randomized trial. JAMA (2011) 3.08
Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam Pract (2000) 3.01
ICU admittance by a rapid response team versus conventional admittance, characteristics, and outcome. Crit Care Med (2013) 2.71
Multicenter implementation of a severe sepsis and septic shock treatment bundle. Am J Respir Crit Care Med (2013) 2.52
Sample size calculations for cluster randomised controlled trials with a fixed number of clusters. BMC Med Res Methodol (2011) 2.47
Surgical delay is a critical determinant of survival in perforated peptic ulcer. Br J Surg (2013) 2.30
Advanced statistics: statistical methods for analyzing cluster and cluster-randomized data. Acad Emerg Med (2002) 2.26
A multicenter, phased, cluster-randomized controlled trial to reduce central line-associated bloodstream infections in intensive care units*. Crit Care Med (2012) 2.18
Regulatory mandates for sepsis care--reasons for caution. N Engl J Med (2014) 2.11
The ProCESS trial--a new era of sepsis management. N Engl J Med (2014) 2.04
Effect of a multifaceted performance feedback strategy on length of stay compared with benchmark reports alone: a cluster randomized trial in intensive care*. Crit Care Med (2013) 1.56
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med (2017) 1.54
A multifaceted program for improving quality of care in intensive care units: IATROREF study. Crit Care Med (2012) 1.52
Improved survival of critically ill cancer patients with septic shock. Intensive Care Med (2003) 1.49
Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting. PLoS One (2011) 1.35
Implementation of a multifaceted sepsis education program in an emerging country setting: clinical outcomes and cost-effectiveness in a long-term follow-up study. Intensive Care Med (2013) 1.32
Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med (2004) 1.27
Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study. Crit Care (2014) 1.00
Influence of surgical treatment timing on mortality from necrotizing soft tissue infections requiring intensive care management. Intensive Care Med (2008) 0.99
Use of a protocolized approach to the management of sepsis can improve time to first dose of antibiotics. J Crit Care (2012) 0.92
Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. Crit Care (2014) 0.90
Quality Improvement Initiative for Severe Sepsis and Septic Shock Reduces 90-Day Mortality: A 7.5-Year Observational Study. Crit Care Med (2017) 0.88
The epidemiology of sepsis during rapid response team reviews in a teaching hospital. Anaesth Intensive Care (2015) 0.82
Subject-level matching for imbalance in cluster randomized trials with a small number of clusters. Pharm Stat (2013) 0.78
Patient and Organizational Factors Associated With Delays in Antimicrobial Therapy for Septic Shock. Crit Care Med (2016) 0.77
Barriers and supportive conditions to improve quality of care for critically ill patients: A team approach to quality improvement. J Crit Care (2015) 0.77
Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet (2015) 1.47
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA (2015) 1.26
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Hyperlactatemia is an independent predictor of mortality and denotes distinct subtypes of severe sepsis and septic shock. J Crit Care (2014) 0.89
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet (2014) 0.88
Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial. JAMA Intern Med (2016) 0.86
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet (2016) 0.83
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One (2015) 0.82
Prevalence of DSM-5 Mild Neurocognitive Disorder in Dementia-Free Older Adults: Results of the Population-Based LIFE-Adult-Study. Am J Geriatr Psychiatry (2016) 0.78
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol (2015) 0.77
Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel) (2017) 0.76
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet (2017) 0.75
The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One (2017) 0.75
Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncol (2016) 0.75